

For consumer information only

# Telflink<sup>®</sup>-40

(Telmisartan Tablets I.P.40 mg)

## Composition:

### Each Uncoated Tablet Contains:

Telmisartan IP.....40mg

Excipients .....q.s.

## Clinical Pharmacology:

Angiotensin II is formed from angiotensin I in a reaction catalyzed by angiotensin-converting enzyme (ACE, kininase II). Angiotensin II is the principal pressor agent of the renin-angiotensin system, with effects that include vasoconstriction, stimulation of synthesis and release of aldosterone, cardiac stimulation, and renal reabsorption of sodium. Telmisartan blocks the vasoconstrictor and aldosterone-secreting effects of angiotensin II by selectively blocking the binding of angiotensin II to the AT1 receptor in many tissues, such as vascular smooth muscle and the adrenal gland. Its action is therefore independent of the pathways for angiotensin II synthesis.

## Indications:

Treatment of Essential Hypertension: Indicated for the treatment of mild to moderate essential hypertension.

## Use in special population:

Geriatrics (> 65 years of age): No dosing adjustment is necessary. It should be recognized, however, that greater sensitivity in some older individuals cannot be ruled out.

Pediatrics (< 18 years of age): Not recommended for use in children below 18 years. The safety and efficacy of telmisartan for use in children below 18 years have not been established.

## Contraindications:

Known hypersensitivity(e.g.,anaphylaxis or angioedema)to telmisartan or any other component of this product

**Precautions and Warnings:**

- Not recommended in pregnancy.
- Hypotension: Correct any volume or salt depletion before initiating therapy. Observe for signs and symptoms of hypotension
- Monitor carefully in patients with impaired hepatic or renal function
- Avoid concomitant use of an ACE inhibitor and angiotensin receptor blocker.

**Adverse effects:**

- Hypertension: The most common adverse events ( $\geq 1\%$ ) reported in hypertension trials are back pain, sinusitis, and diarrhea.
- Cardiovascular risk reduction: The serious adverse events ( $\geq 1\%$ ) reported in cardiovascular risk reduction trials were intermittent claudication and skin ulcer.

**Overdosage:**

The over dosage with Telflink-AM tablets would be hypotension, dizziness and tachycardia; bradycardia could occur from parasympathetic (vagal) stimulation.

**SCHEDULE H PRESCRIPTION DRUG-CAUTION** Not to be sold by retail without Prescription of a Registered Medical Practitioner.

Keep all medicines out of reach of children.

**WARNING:** When pregnancy is detected. Telmisartan should be discontinued as soon as possible, it can cause injury and even death to the developing fetus, when used in pregnancy during second and third trimester of pregnancy.

**For Therapeutic use.**

**Route of administration:** Oral.

**Type of tablet:** Uncoated Tablet.

**Dosage:** As directed by the physician.

**Storage:** Store in cool, dry & dark place.

**Presentation:** Telflink-40 uncoated tablet available as 10x10 Tablet.

**Marketed By:**



**EPIONE PHARMACEUTICALS PVT.LTD.**

**804, Suyog Center, Gultekdi, Pune-411037 (MH), India.**